Thomasf Ryan Jr News Today

Repligen Co. (NASDAQ:RGEN – Get Rating) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 2,780,000 shares, a growth of 21.4% from the April 15th total of 2,290,000 shares. Based on an average trading volume of 519,600 shares, the days-to-cover […]

Equities analysts expect Repligen Co. (NASDAQ:RGEN – Get Rating) to announce earnings of $0.73 per share for the current quarter, Zacks reports. Six analysts have made estimates for Repligen’s earnings, with the highest EPS estimate coming in at $0.80 and the lowest estimate coming in at $0.66. Repligen reported earnings per share of $0.79 in […]

Equities analysts expect Repligen Co. (NASDAQ:RGEN – Get Rating) to post sales of $183.55 million for the current quarter, according to Zacks. Six analysts have issued estimates for Repligen’s earnings. The lowest sales estimate is $171.50 million and the highest is $193.21 million. Repligen posted sales of $142.84 million during the same quarter last year, […]

Wall Street analysts expect Repligen Co. (NASDAQ:RGEN – Get Rating) to post earnings per share (EPS) of $0.72 for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Repligen’s earnings. The lowest EPS estimate is $0.66 and the highest is $0.76. Repligen reported earnings per share of $0.68 during the same […]

National Asset Management Inc. boosted its stake in Repligen Co. (NASDAQ:RGEN – Get Rating) by 16.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,865 shares of the biotechnology company’s stock after buying an additional 257 shares during the quarter. National Asset Management […]

Repligen Co. (NASDAQ:RGEN – Get Rating) has received an average rating of “Buy” from the nine analysts that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among analysts that have […]

Wall Street brokerages expect that Repligen Co. (NASDAQ:RGEN – Get Rating) will post $183.55 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Repligen’s earnings, with the lowest sales estimate coming in at $171.50 million and the highest estimate coming in at $193.21 million. Repligen posted […]

Wall Street analysts expect that Repligen Co. (NASDAQ:RGEN – Get Rating) will announce earnings per share (EPS) of $0.72 for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Repligen’s earnings, with the highest EPS estimate coming in at $0.76 and the lowest estimate coming in at $0.66. Repligen posted earnings […]

IFP Advisors Inc decreased its holdings in Repligen Co. (NASDAQ:RGEN – Get Rating) by 91.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 126 shares of the biotechnology company’s stock after selling 1,398 shares during the quarter. IFP Advisors Inc’s holdings in Repligen were worth $35,000 at the end of the most recent reporting […]

LRT Capital Management LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN – Get Rating) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 16,710 shares of the biotechnology company’s stock, valued at approximately $4,425,000. Repligen makes up approximately 3.4% of LRT Capital Management LLC’s holdings, making the stock its 9th biggest holding. […]